ChemoCentryx receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
50.70
-0.02(-0.04%)
- Volume:2,367,255
- Day's Range:50.62 - 50.83
- 52 wk Range:13.11 - 51.06
CCXI Overview
- Prev. Close
- 50.72
- Day's Range
- 50.62-50.83
- Revenue
- 37.28M
- Open
- 50.69
- 52 wk Range
- 13.11-51.06
- EPS
- -1.89
- Volume
- 2,367,255
- Market Cap
- 3.62B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 2,120,050
- P/E Ratio
- -26.81
- Beta
- 1.66
- 1-Year Change
- 262.29%
- Shares Outstanding
- 71,357,303
- Next Earnings Date
- Nov 08, 2022
What is your sentiment on ChemoCentryx?
or
Vote to see community's results!
ChemoCentryx Inc Analysis
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (NASDAQ:ENTA) came out with a quarterly loss of $1.48 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.41 per...
- ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?
ChemoCentryx (NASDAQ:CCXI) CCXI shares ended the last trading session 5.4% higher at $19.60. The jump came on an impressive volume with a higher-than-average number of shares...
- 3 “Perfect 10” Healthcare Stocks That Have Plenty Of Growth On Tap
Disconnected. This seems to be the best way to describe the current economic environment. Amid high levels of unemployment and tanking earnings, stocks aren’t just hanging in...
ChemoCentryx Inc Company Profile
ChemoCentryx Inc Company Profile
ChemoCentryx, Inc. is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. The Company is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The Company's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. It markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.15 | 8.15 | 7.85 | -0.21 | -2.56% | 3.62M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 31.89 | 31.89 | 30.71 | -0.86 | -2.63% | 4.50M | NYSE | |||
| 1.16 | 1.19 | 1.15 | -0.0500 | -4.13% | 1.71M | NYSE | |||
| 1.09 | 1.09 | 1.05 | -0.0100 | -0.91% | 81.52K | NYSE | |||
| 45.51 | 45.51 | 44.78 | -0.75 | -1.62% | 1.19M | NYSE | |||
| 3.54 | 3.55 | 3.47 | -0.060 | -1.67% | 7.83M | NYSE | |||
| 20.34 | 20.52 | 19.80 | +0.21 | +1.07% | 707.26K | NASDAQ | |||
| 7.41 | 7.54 | 6.73 | +0.540 | +7.86% | 4.48M | NYSE | |||
| 14.32 | 15.06 | 13.37 | +1.38 | +10.62% | 77.96M | NASDAQ | |||
| 49.75 | 49.85 | 47.44 | -1.14 | -2.24% | 1.50M | NYSE | |||
| 15.25 | 15.30 | 15.00 | +0.03 | +0.20% | 1.61M | OTC Markets | |||
| 0.78 | 0.79 | 0.776 | -0.010 | -1.27% | 5.42K | NASDAQ | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 42.84 | 42.85 | 42.42 | -0.68 | -1.55% | 1.83M | NYSE |
- Jul 12, 2022, 09:12Hi i been in CCXI SINCE $4 - 7 -11 , enjoyed the rise to $42, sold only 25 pct as i ALSO have a 55/65 usd target.i was very surprised to see it back through perceived support usd 25, and bought more at usd 19....Now i am very sure we will see usd30 soon, but it looks like a very bumpy road ....having this har breaking back up thec25/27 usd rangeANY COMMENTS PLEASE.
- Aug 05, 2022, 08:51Yea what a lovely day, Bid of usd 52 from large company, abit below the preferred target 55/60 , but guess in todays world 110 pct is enough. As foreign investor i sold my part at 50.50 and says thank you since the trip started at 5 and 11👍🏻🍀👍🏻
- Dec 28, 2021, 20:21Gravy train to $60s is about to happen soon. Those reading this now and not getting in will be kickin themselves shortly after. This will run like moderna come 2022.
- Jul 12, 2022, 09:10Hi i been in CCXI SINCE $4 - 7 -11 , enjoyed the rise to $42, sold only 25 pct as i ALSO have a 55/65 usd target.i was very surprised to see it back through perceived support usd 25, and bought more at usd 19....Now i am very sure we will see usd30 soon, but it looks like a very bumpy road ....having this har breaking back up thec25/27 usd rangeANY COMMENTS PLEASE.
- Dec 22, 2021, 22:38Closer and closer to $60s soon.
- Nov 26, 2021, 19:41$60s incoming
- Nov 29, 2021, 20:50why?
- Nov 30, 2021, 21:28why not, it has been on $70 before
- Dec 11, 2021, 02:34Benjamin Oehlenschlägerit was fake pump price
- Nov 03, 2021, 07:48This should run up some more when approved by the EU's EMA....$37 now with a $107 price target. Definitely a no braine.
- Oct 21, 2021, 22:02sell it while you can get something....
- Oct 21, 2021, 13:21still stay long.
- Oct 15, 2021, 20:15Time to buy right now
- Oct 12, 2021, 23:19This is my new moderna
- Oct 12, 2021, 20:25TP 28